CORRECTION: iRadimed Raises FY2026 Adj EPS Guidance from $2.06-$2.21 to $2.09-$2.24 vs $2.08 Est; Affirms FY2026 Sales Guidance of $91.000M-$96.000M vs $91.300M Est
iRadimed (NASDAQ:IRMD) raises FY2026 Adj EPS guidance from $2.06-$2.21 to $2.09-$2.24 vs $2.08 analyst estimate. Raises FY2026 sales outlook from $91.000 million-$96.000 million to $91.000 billion-$96.000 billion vs
